Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
FDA Approval Insights: Ponatinib in Ph+ ALL
Insider Insights: Unveiling Takeaways from AACR 2024
CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma
Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma